Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...